APA (7th ed.) Citation

Schultheis, B., & Hofheinz, R. (2017). Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: A multicenter, randomized phase IIb study. Annals of oncology, 28(10), . https://doi.org/10.1093/annonc/mdx343

Chicago Style (17th ed.) Citation

Schultheis, Beate, and Ralf-Dieter Hofheinz. "Gemcitabine Combined with the Monoclonal Antibody Nimotuzumab Is an Active First-line Regimen in KRAS Wildtype Patients with Locally Advanced or Metastatic Pancreatic Cancer: A Multicenter, Randomized Phase IIb Study." Annals of Oncology 28, no. 10 (2017). https://doi.org/10.1093/annonc/mdx343.

MLA (9th ed.) Citation

Schultheis, Beate, and Ralf-Dieter Hofheinz. "Gemcitabine Combined with the Monoclonal Antibody Nimotuzumab Is an Active First-line Regimen in KRAS Wildtype Patients with Locally Advanced or Metastatic Pancreatic Cancer: A Multicenter, Randomized Phase IIb Study." Annals of Oncology, vol. 28, no. 10, 2017, https://doi.org/10.1093/annonc/mdx343.